Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2011-03-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
NCT00540566
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Skin Tumor Biomarkers by Mass Spectrometry Imaging
NCT06227416
Study to Examine Lesions of the Skin Using Confocal Laser Microscopy
NCT06598137
In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin
NCT00588315
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Researchers can test the hypothesis that expression of key metabolic enzymes is reduced and/or lost during skin cancer progression. Total ribonucleic acid, a single-stranded biologic molecule involved in gene transcription, regulation, and translation, can be isolated from biopsied skin specimens. Quantitative Real-Time can be performed to determine the expression levels of several key metabolic enzymes.
Metabolic enzymes regulate several vital signaling pathways in the human body. Some examples include hormone and bioactive lipid regulation. Aberrant regulation of these signaling pathways can lead to human diseases including cancer.
Recent evidence has shown that metabolic enzyme call UGT in the genes call UDP-glucuronosyltransferases were shown to have significantly reduced expression in breast tumors compared with normal breast tissue from the same patients This observed loss of expression is hypothesized to be causal as these two enzymes are responsible for estrogen metabolism.
However, relatively little is known about metabolic enzymes and skin cancer. We have preliminary data that UGT enzyme expression is lost during melanoma progression which allows deregulated lipoxygenase signaling.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
skin specimen
skin specimen
skin specimen
skin specimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
skin specimen
skin specimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have normal skin and a skin lesion of interest
* Willing to have skin biopsies on those areas
Exclusion Criteria
* Pregnant women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chao Family Comprehensive Cancer Center
OTHER
Beckman Laser Institute University of California Irvine
OTHER
University of California, Irvine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beckman Laser Institute and Medical Center
Kirsten Kelly, M.D., Professor of Dermatology and Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristen Kelly, MD
Role: PRINCIPAL_INVESTIGATOR
Beckman Laser Institute, UCI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beckman Laser Institute
Irvine, California, United States
Gottschalk Medical Plaza, 1 Medical Plaza Drive
Irvine, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEED Grant 405181-66496
Identifier Type: OTHER
Identifier Source: secondary_id
20107851
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.